A model of GLP-1 action on insulin secretion in nondiabetic subjects

Chiara Dalla Man, Francesco Micheletto, Airani Sathananthan, Robert A. Rizza, Adrian Vella, Claudio Cobelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Glucagon-like peptide-1 (GLP-1)-based therapies for diabetes have aroused interest because of their effects on insulin secretion and glycemic control. However, a mechanistic model enabling quantitation of pancreatic response to GLP-1 has never been developed. To develop such a model we studied 88 healthy individuals (age 26.3 ∓ 0.6 yr, BMI 24.9 ∓ 0.4 kg/m2) by use of a hyperglycemic clamp. A variable infusion maintained glucose concentrations at 150 mg/dl for 240 min. At 120 min, an intravenous infusion of GLP-1 was started (0.75 pmol·kg-1 ·min-1 from 120-180 min, 1.5 pmol·kg-1 ·min-1 from 181-240 min). Consequently, plasma C-peptide concentration rose from 1,852.0 ∓ 62.8 pmol/l at 120 min to 4,272.2 ∓ 176.4 pmol/l at 180 min and to 6,995.8 ∓ 323.5 pmol/l at 240 min. Four models of GLP-1 action on insulin secretion were considered. All models share the common assumption that insulin secretion is made up of two components, one proportional to glucose rate of change through dynamic responsivity, Φd, and one proportional to glucose through static responsivity, Φs, but differing by modality of GLP-1 control. The model that best fit C-peptide data assumes that above-basal insulin secretion depends linearly on GLP-1 concentration and its rate of change. An index (Π) measuring the percentage increase of secretion due to GLP-1 is derived. Before GLP-1 infusion, Φd = 245.7 ± 15.6 10-9 and Φs = 25.2 ∓ 1.4 10-9 min-1. Under GLP-1 stimulus, Π = 12.6 ± 0.71% per pmol/l, meaning that an increase of 5 pmol/l in peripheral GLP-1 concentrations induces an ∼60% increase in over-basal insulin secretion.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume298
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Glucagon-Like Peptide 1
Insulin
C-Peptide
Glucose
Intravenous Infusions

Keywords

  • β-cell responsivity
  • C-peptide
  • Glucagon-like peptide-1
  • Hyperglycemic clamp
  • Incretins
  • Parameter estimation

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism

Cite this

A model of GLP-1 action on insulin secretion in nondiabetic subjects. / Dalla Man, Chiara; Micheletto, Francesco; Sathananthan, Airani; Rizza, Robert A.; Vella, Adrian; Cobelli, Claudio.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 298, No. 6, 06.2010.

Research output: Contribution to journalArticle

Dalla Man, Chiara ; Micheletto, Francesco ; Sathananthan, Airani ; Rizza, Robert A. ; Vella, Adrian ; Cobelli, Claudio. / A model of GLP-1 action on insulin secretion in nondiabetic subjects. In: American Journal of Physiology - Endocrinology and Metabolism. 2010 ; Vol. 298, No. 6.
@article{2fc73d211b73459da7db42d897cd3d09,
title = "A model of GLP-1 action on insulin secretion in nondiabetic subjects",
abstract = "Glucagon-like peptide-1 (GLP-1)-based therapies for diabetes have aroused interest because of their effects on insulin secretion and glycemic control. However, a mechanistic model enabling quantitation of pancreatic response to GLP-1 has never been developed. To develop such a model we studied 88 healthy individuals (age 26.3 ∓ 0.6 yr, BMI 24.9 ∓ 0.4 kg/m2) by use of a hyperglycemic clamp. A variable infusion maintained glucose concentrations at 150 mg/dl for 240 min. At 120 min, an intravenous infusion of GLP-1 was started (0.75 pmol·kg-1 ·min-1 from 120-180 min, 1.5 pmol·kg-1 ·min-1 from 181-240 min). Consequently, plasma C-peptide concentration rose from 1,852.0 ∓ 62.8 pmol/l at 120 min to 4,272.2 ∓ 176.4 pmol/l at 180 min and to 6,995.8 ∓ 323.5 pmol/l at 240 min. Four models of GLP-1 action on insulin secretion were considered. All models share the common assumption that insulin secretion is made up of two components, one proportional to glucose rate of change through dynamic responsivity, Φd, and one proportional to glucose through static responsivity, Φs, but differing by modality of GLP-1 control. The model that best fit C-peptide data assumes that above-basal insulin secretion depends linearly on GLP-1 concentration and its rate of change. An index (Π) measuring the percentage increase of secretion due to GLP-1 is derived. Before GLP-1 infusion, Φd = 245.7 ± 15.6 10-9 and Φs = 25.2 ∓ 1.4 10-9 min-1. Under GLP-1 stimulus, Π = 12.6 ± 0.71{\%} per pmol/l, meaning that an increase of 5 pmol/l in peripheral GLP-1 concentrations induces an ∼60{\%} increase in over-basal insulin secretion.",
keywords = "β-cell responsivity, C-peptide, Glucagon-like peptide-1, Hyperglycemic clamp, Incretins, Parameter estimation",
author = "{Dalla Man}, Chiara and Francesco Micheletto and Airani Sathananthan and Rizza, {Robert A.} and Adrian Vella and Claudio Cobelli",
year = "2010",
month = "6",
doi = "10.1152/ajpendo.00705.2009",
language = "English (US)",
volume = "298",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - A model of GLP-1 action on insulin secretion in nondiabetic subjects

AU - Dalla Man, Chiara

AU - Micheletto, Francesco

AU - Sathananthan, Airani

AU - Rizza, Robert A.

AU - Vella, Adrian

AU - Cobelli, Claudio

PY - 2010/6

Y1 - 2010/6

N2 - Glucagon-like peptide-1 (GLP-1)-based therapies for diabetes have aroused interest because of their effects on insulin secretion and glycemic control. However, a mechanistic model enabling quantitation of pancreatic response to GLP-1 has never been developed. To develop such a model we studied 88 healthy individuals (age 26.3 ∓ 0.6 yr, BMI 24.9 ∓ 0.4 kg/m2) by use of a hyperglycemic clamp. A variable infusion maintained glucose concentrations at 150 mg/dl for 240 min. At 120 min, an intravenous infusion of GLP-1 was started (0.75 pmol·kg-1 ·min-1 from 120-180 min, 1.5 pmol·kg-1 ·min-1 from 181-240 min). Consequently, plasma C-peptide concentration rose from 1,852.0 ∓ 62.8 pmol/l at 120 min to 4,272.2 ∓ 176.4 pmol/l at 180 min and to 6,995.8 ∓ 323.5 pmol/l at 240 min. Four models of GLP-1 action on insulin secretion were considered. All models share the common assumption that insulin secretion is made up of two components, one proportional to glucose rate of change through dynamic responsivity, Φd, and one proportional to glucose through static responsivity, Φs, but differing by modality of GLP-1 control. The model that best fit C-peptide data assumes that above-basal insulin secretion depends linearly on GLP-1 concentration and its rate of change. An index (Π) measuring the percentage increase of secretion due to GLP-1 is derived. Before GLP-1 infusion, Φd = 245.7 ± 15.6 10-9 and Φs = 25.2 ∓ 1.4 10-9 min-1. Under GLP-1 stimulus, Π = 12.6 ± 0.71% per pmol/l, meaning that an increase of 5 pmol/l in peripheral GLP-1 concentrations induces an ∼60% increase in over-basal insulin secretion.

AB - Glucagon-like peptide-1 (GLP-1)-based therapies for diabetes have aroused interest because of their effects on insulin secretion and glycemic control. However, a mechanistic model enabling quantitation of pancreatic response to GLP-1 has never been developed. To develop such a model we studied 88 healthy individuals (age 26.3 ∓ 0.6 yr, BMI 24.9 ∓ 0.4 kg/m2) by use of a hyperglycemic clamp. A variable infusion maintained glucose concentrations at 150 mg/dl for 240 min. At 120 min, an intravenous infusion of GLP-1 was started (0.75 pmol·kg-1 ·min-1 from 120-180 min, 1.5 pmol·kg-1 ·min-1 from 181-240 min). Consequently, plasma C-peptide concentration rose from 1,852.0 ∓ 62.8 pmol/l at 120 min to 4,272.2 ∓ 176.4 pmol/l at 180 min and to 6,995.8 ∓ 323.5 pmol/l at 240 min. Four models of GLP-1 action on insulin secretion were considered. All models share the common assumption that insulin secretion is made up of two components, one proportional to glucose rate of change through dynamic responsivity, Φd, and one proportional to glucose through static responsivity, Φs, but differing by modality of GLP-1 control. The model that best fit C-peptide data assumes that above-basal insulin secretion depends linearly on GLP-1 concentration and its rate of change. An index (Π) measuring the percentage increase of secretion due to GLP-1 is derived. Before GLP-1 infusion, Φd = 245.7 ± 15.6 10-9 and Φs = 25.2 ∓ 1.4 10-9 min-1. Under GLP-1 stimulus, Π = 12.6 ± 0.71% per pmol/l, meaning that an increase of 5 pmol/l in peripheral GLP-1 concentrations induces an ∼60% increase in over-basal insulin secretion.

KW - β-cell responsivity

KW - C-peptide

KW - Glucagon-like peptide-1

KW - Hyperglycemic clamp

KW - Incretins

KW - Parameter estimation

UR - http://www.scopus.com/inward/record.url?scp=77952588236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952588236&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00705.2009

DO - 10.1152/ajpendo.00705.2009

M3 - Article

C2 - 20179243

AN - SCOPUS:77952588236

VL - 298

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 6

ER -